mRNA-1083 is under development for the prevention of influenza virus infection caused by influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria strains and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in 18 to 79 years of age group. It is a combination vaccine of mRNA-1283, which encodes Receptor Binding Doman (RBD) and N-Terminal Domain (NTD) of the spike protein and mRNA-1010, which encodes hemagglutinin (HA) glycoproteins of influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria-lineages. It is administered through intramuscular route in the form of sterile liquid for injection
1283和1010勾兑的1083.
估计是后面的拳头产品，至于会不会用上预测点位呢，不知道。
但是本坏人还是要说那句话，预测出来了就能够具有良好的免疫效果吗？要是哪一个突变，它的效果就是降低疫苗的效果了。照抄毒株就是完全正确的嘛。我还是更期待能够具有其他沙贝病毒序列的抗原的疫苗登场。
平心而论，换RBD+NTD 比隔壁B1-B5死守全长好点。不知道B6 B7是什么结构
Reshefp/闭挨踢 162B6/7 抬走，埋了
妄图依靠全程对抗OAS，提升免疫广度，没救了。
